JP4845166B2 - ゲルを形成する濃度の性腺刺激ホルモン放出ホルモン拮抗物質 - Google Patents
ゲルを形成する濃度の性腺刺激ホルモン放出ホルモン拮抗物質 Download PDFInfo
- Publication number
- JP4845166B2 JP4845166B2 JP2003511855A JP2003511855A JP4845166B2 JP 4845166 B2 JP4845166 B2 JP 4845166B2 JP 2003511855 A JP2003511855 A JP 2003511855A JP 2003511855 A JP2003511855 A JP 2003511855A JP 4845166 B2 JP4845166 B2 JP 4845166B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- concentration
- solvent
- solution
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Description
Ac アセチル
DNal D−β−(2−ナフチル)アラニン
DCpa D−4−クロロフェニルアラニン
DPal D−β−(3−ピリジル)アラニン
Ser セリン
Aph(X1) ω−アミノ基が置換基X1を有する4−アミノフェニルアラニン
DAph(X2) ω−アミノ基が置換基X2を有するD−4−アミノフェニルアラニン
Leu ロイシン
Lys(iPr)− Nω−イソプロピルリシン
Pro プロリン
DAla−NH2 D−アラニンアミド
置換基X1及びX2は、RがH又は低級(C1−C6)アルキル基、D−及びL−ヒドロオロチル(D−及びL−Hor)基、及びD−及びL−2−イミダゾリドン−4−カルボニル(D−及びL−imz)基である、カルバモイル基−CONHRから独立して選択される。
本発明の組成物において使用するペプチドは、米国特許第5,925,730号に述べられている方法に従って製造することができる。特に、ペプチドAc−DNal−DCpa−DPal−Ser−Aph(L−Hor)−DAph(CONH2)−Leu−Lys(iPr)−Pro−DAla−NH2(「ペプチド1」)を前記米国特許の実施例1の方法に従って製造し、その酢酸塩として単離した。
ペプチド1を様々な濃度で水に溶解し、生じた溶液を長期間にわたって室温で放置した。肉眼検査によってゲル形成を判定した。その所見を表1に要約する。
ペプチド1を様々な濃度で5%マンニトールに溶解し、ラットに皮下注射した。動物を24時間後に犠牲剖検し、注射部位を切開して検査した。ゲルの沈着物が認められたときは、それらを切除して計量し、ゲル形成の完全性を評価した。0.3mg/ml超えるペプチド濃度に関して有意のゲル形成を認めた。
ペプチド1を5%マンニトールに溶解する(25mg/ml)。3匹の卵巣摘出アカゲザルを皮下注射によってこの溶液(80μg/kg)で処置する。その後101日間、血清中LHレベルを測定する。その結果を表2に要約する。
5A−注射用溶液
ペプチドAc−DNal−DCpa−DPal−Ser−Aph(L−Hor)−DAph(CONH2)−Leu−Lys(iPr)−Pro−DAla−NH2酢酸塩(ペプチド1、実施例1参照)51.84g及びマンニトール500gを無菌水10リットルに溶解して溶液を調製し、5%マンニトール水溶液中ペプチド5mg/ml(遊離塩基として算定)の最終濃度を得る。その溶液を0.2ミクロンフィルターでろ過し、5000のガラス製バイアルに分配して、各々2mlの、前記溶液の5000の個別用量を作製する。
ペプチドAc−DNal−DCpa−DPal−Ser−Aph(L−Hor)−DAph(CONH2)−Leu−Lys(iPr)−Pro−DAla−NH2(ペプチド1、実施例1参照)414.7g及びマンニトール250gを無菌水10リットルに溶解して溶液を調製する。その溶液を0.2ミクロンフィルターでろ過し、5000のガラス製バイアルに分配して、その後凍結乾燥する。
Claims (14)
- 一般式(1):
Ac-DNal-DCpa-DPal-Ser-Aph(L-Hor)-DAph(CONH2)-Leu-Lys(iPr)-Pro-DAla-NH2(1)
で表されるGnRH拮抗ペプチド又は医薬適合性のその塩の医薬適合性の溶媒中の溶液の形態の注射用医薬組成物であって、前記ペプチドの溶液中の濃度が、前記ペプチドがゲル形態ではないが注射後ゲルを形成するよう少なくとも25mg/mlの濃度であって、前記ゲルが少なくとも2週間にわたって前記ペプチドを放出するデポー剤として働く注射用医薬組成物。 - 溶液中の前記ペプチドの濃度が120mg/ml以下である、請求項1に記載の組成物。
- 溶液中の前記ペプチドの濃度が80mg/ml以下である、請求項1又は2に記載の組成物。
- 請求項1で定義されたGnRH拮抗ペプチド又はその塩を含有する第一コンポーネント及びそれらのための医薬適合性の溶媒を含有する第二コンポーネントを含むパーツの医薬キットであって、第一コンポーネント及び第二コンポーネントは混合され請求項1から3いずれかに記載の注射用医薬組成物を提供する医薬キット。
- 前記溶液中の前記ペプチドの濃度が120mg/ml以下である、請求項4に記載のキット。
- 前記ペプチドの濃度が80mg/ml以下である、請求項5に記載のキット。
- 前記ペプチドの濃度が40mg/ml以下である、請求項1から3のいずれかに記載の組成物。
- 前記溶媒が、水、又は溶媒の少なくとも90重量%が水であるような水と第二の溶媒の混合物である、請求項1から3及び7のいずれかに記載の組成物。
- 前記ペプチドがその塩酸塩又は酢酸塩の形態である、請求項1から3、7及び8のいずれかに記載の組成物。
- 良性前立腺過形成、前立腺癌、エストロゲン依存性乳癌、子宮内膜症又は性的早熟の治療のための、避妊薬としての使用又は体外受精プログラムにおける使用のための、又は性犯罪者の治療のための、請求項1から3及び7から9のいずれかに記載の組成物。
- 前記ペプチドの濃度が40mg/ml以下である、請求項4から6のいずれかに記載のキット。
- 前記溶媒が、水、又は溶媒の少なくとも90重量%が水であるような水と第二の溶媒の混合物である、請求項4から6及び11のいずれかに記載のキット。
- 前記ペプチドがその塩酸塩又は酢酸塩の形態である、請求項4から6、11及び12いずれかに記載のキット。
- 良性前立腺過形成、前立腺癌、エストロゲン依存性乳癌、子宮内膜症又は性的早熟の治療のための、避妊薬としての使用又は体外受精プログラムにおける使用のための、又は性犯罪者の治療のための、請求項4から6及び11から13のいずれかに記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0117057.0A GB0117057D0 (en) | 2001-07-12 | 2001-07-12 | Pharmaceutical composition |
GB0117057.0 | 2001-07-12 | ||
PCT/GB2002/003116 WO2003006049A1 (en) | 2001-07-12 | 2002-07-08 | Gonadotropin releasing hormone antagonists in gel-forming concentrations |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005511491A JP2005511491A (ja) | 2005-04-28 |
JP2005511491A5 JP2005511491A5 (ja) | 2007-05-24 |
JP4845166B2 true JP4845166B2 (ja) | 2011-12-28 |
Family
ID=9918396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003511855A Expired - Lifetime JP4845166B2 (ja) | 2001-07-12 | 2002-07-08 | ゲルを形成する濃度の性腺刺激ホルモン放出ホルモン拮抗物質 |
Country Status (13)
Country | Link |
---|---|
US (4) | US20050245455A1 (ja) |
EP (1) | EP1404357B1 (ja) |
JP (1) | JP4845166B2 (ja) |
AR (1) | AR036337A1 (ja) |
AT (1) | ATE452648T1 (ja) |
DE (1) | DE60234831D1 (ja) |
DK (1) | DK1404357T3 (ja) |
ES (1) | ES2338217T3 (ja) |
GB (1) | GB0117057D0 (ja) |
MY (1) | MY139203A (ja) |
PT (1) | PT1404357E (ja) |
UY (1) | UY27378A1 (ja) |
WO (1) | WO2003006049A1 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
CN100509053C (zh) | 2002-09-27 | 2009-07-08 | 赞塔里斯有限公司 | 持续释放的药物活性肽施用形式及其制备方法 |
EP3025722B1 (en) | 2003-10-03 | 2020-05-27 | Thorn BioScience, LLC | Process for the synchronization of ovulation for timed breeding without heat detection |
GB0511269D0 (en) | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
CA2671925A1 (en) * | 2006-12-21 | 2008-07-10 | Stryker Corporation | Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents |
TWI442932B (zh) | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以GnRH拮抗劑治療攝護腺癌的方法 |
PL2421545T3 (pl) | 2009-04-23 | 2018-05-30 | Jbs United Animal Health Ii Llc | Sposób i kompozycja do synchronizacji czasu inseminacji |
EP2424503B1 (en) * | 2009-05-01 | 2017-07-05 | Ferring BV | Composition for the treatment of prostate cancer |
JO3550B1 (ar) * | 2009-05-01 | 2020-07-05 | Ferring Int Center Sa | مركب لمعالجة سرطان البروستاتا |
TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
PL2632934T3 (pl) | 2010-10-27 | 2017-06-30 | Ferring B.V. | Sposób wytwarzania degareliksu i jego związków pośrednich |
JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
WO2013104745A1 (en) * | 2012-01-13 | 2013-07-18 | Ferring Bv | Pharmaceutical composition |
AR092840A1 (es) | 2012-06-01 | 2015-05-06 | Ferring Bv | Elaboracion de degarelix |
ITMI20121638A1 (it) * | 2012-10-02 | 2014-04-03 | Marco Sbracia | Utilizzo di degarelix nel trattamento dell'endometriosi e di patologie ad essa correlate |
WO2014085674A1 (en) | 2012-11-28 | 2014-06-05 | Jbs United Animal Health Ii Llc | Method for synchronizing time of insemination in gilts |
US10681261B2 (en) * | 2012-11-30 | 2020-06-09 | 3I Avi, Llc | Inspection system |
TW201625218A (zh) * | 2014-04-18 | 2016-07-16 | Jbs聯合動物保健有限責任公司 | 製造含gnrh凝膠之方法 |
US20200000872A1 (en) * | 2017-01-30 | 2020-01-02 | Antev Limited | A composition comprising at least one gnrh antagonist |
WO2019110688A1 (en) | 2017-12-05 | 2019-06-13 | Ferring B.V. | A composition comprising degarelix for use in the treatment of breast cancer |
EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US200486A (en) * | 1878-02-19 | Improvement in apparatus for attaching harness to the shafts | ||
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
DE593491T1 (de) * | 1991-04-25 | 1994-11-17 | Romano S.-Cergue Deghenghi | LHRH-Antagonisten. |
SI9300468A (en) * | 1992-10-14 | 1994-06-30 | Hoffmann La Roche | Injectable composition for the sustained release of biologically active compounds |
US5506207A (en) * | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
US5595760A (en) * | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US5860957A (en) * | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
US5925730A (en) * | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
US5821230A (en) * | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
FR2776520B1 (fr) * | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
US20020103131A1 (en) * | 2001-01-26 | 2002-08-01 | Jacobson Jill D. | Prevention of diabetes by administration of GnRH antagonists |
GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
AR042815A1 (es) * | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
EP1891964A1 (en) * | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
WO2009102720A1 (en) * | 2008-02-11 | 2009-08-20 | Safety Syringes, Inc. | Reconstitution means for safety device |
TWI442932B (zh) * | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以GnRH拮抗劑治療攝護腺癌的方法 |
EP2424503B1 (en) * | 2009-05-01 | 2017-07-05 | Ferring BV | Composition for the treatment of prostate cancer |
TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
PL2632934T3 (pl) * | 2010-10-27 | 2017-06-30 | Ferring B.V. | Sposób wytwarzania degareliksu i jego związków pośrednich |
EP2447276A1 (en) * | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
JO3755B1 (ar) * | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
PL2731607T3 (pl) * | 2011-07-15 | 2018-03-30 | Ferring B.V. | Sposób koordynacji czasu kolonoskopii, w którym podaje się kompozycję pikosiarczanową |
-
2001
- 2001-07-12 GB GBGB0117057.0A patent/GB0117057D0/en not_active Ceased
-
2002
- 2002-07-03 MY MYPI20022511A patent/MY139203A/en unknown
- 2002-07-08 DK DK02749000.2T patent/DK1404357T3/da active
- 2002-07-08 US US10/483,325 patent/US20050245455A1/en not_active Abandoned
- 2002-07-08 DE DE60234831T patent/DE60234831D1/de not_active Expired - Lifetime
- 2002-07-08 JP JP2003511855A patent/JP4845166B2/ja not_active Expired - Lifetime
- 2002-07-08 PT PT02749000T patent/PT1404357E/pt unknown
- 2002-07-08 AT AT02749000T patent/ATE452648T1/de active
- 2002-07-08 WO PCT/GB2002/003116 patent/WO2003006049A1/en active Application Filing
- 2002-07-08 EP EP02749000A patent/EP1404357B1/en not_active Expired - Lifetime
- 2002-07-08 ES ES02749000T patent/ES2338217T3/es not_active Expired - Lifetime
- 2002-07-08 US US10/380,623 patent/US20040038903A1/en not_active Abandoned
- 2002-07-11 UY UY27378A patent/UY27378A1/es not_active Application Discontinuation
- 2002-07-11 AR ARP020102599A patent/AR036337A1/es not_active Application Discontinuation
-
2008
- 2008-06-11 US US12/155,897 patent/US20090018085A1/en not_active Abandoned
-
2010
- 2010-10-08 US US12/901,270 patent/US20110053846A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE452648T1 (de) | 2010-01-15 |
EP1404357A1 (en) | 2004-04-07 |
GB0117057D0 (en) | 2001-09-05 |
AR036337A1 (es) | 2004-09-01 |
JP2005511491A (ja) | 2005-04-28 |
US20040038903A1 (en) | 2004-02-26 |
WO2003006049A1 (en) | 2003-01-23 |
US20050245455A1 (en) | 2005-11-03 |
US20090018085A1 (en) | 2009-01-15 |
EP1404357B1 (en) | 2009-12-23 |
DE60234831D1 (de) | 2010-02-04 |
MY139203A (en) | 2009-08-28 |
DK1404357T3 (da) | 2010-05-03 |
UY27378A1 (es) | 2003-02-28 |
ES2338217T3 (es) | 2010-05-05 |
PT1404357E (pt) | 2010-03-16 |
US20110053846A1 (en) | 2011-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4845166B2 (ja) | ゲルを形成する濃度の性腺刺激ホルモン放出ホルモン拮抗物質 | |
JP7297116B2 (ja) | 前立腺癌を治療するための組成物 | |
JP2008291037A (ja) | ペプチド類の水性配合物 | |
JP2008195739A (ja) | 非水性プロトン性ペプチド配合物 | |
KR100633280B1 (ko) | 약제학적 활성 펩티드의 서방형 투여 형태 및 이의 제조 방법 | |
KR20140091652A (ko) | 안정적이며 바로 사용 가능한 세트로레릭스 주사액 | |
JP7085958B2 (ja) | 前立腺癌を治療するための組成物 | |
JP7181318B2 (ja) | テベレリクス-tfa組成物 | |
JP2021529164A (ja) | 復元可能なテベレリクス−tfa組成物 | |
CN114903902A (zh) | GnRH受体拮抗剂联合雄激素受体拮抗剂在制备治疗***癌药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070328 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20070328 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20070420 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070515 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070717 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070724 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071115 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080530 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080716 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20090109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110120 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110125 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20110610 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111007 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141021 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4845166 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141021 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |